March 6, 2015 writer


Québec City, March 6, 2015 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”), an innovator in sterilization technology for medical devices in healthcare settings, announced today that it will showcase its new STERIZONE® VP4 Sterilizer at the AORN Surgical Conference & Expo 2015, held in Denver, Colorado from March 7 to 11, 2015. This annual convention of AORN (the Association of periOperative Registered Nurses) brings together approximately 6,000 registrants and is the largest U.S. nursing convention of stakeholders in the performance, efficacy and efficiency of low-temperature sterilization processes.

“While negotiations aimed at securing strong territory sales and service coverage continue, participation in a prominent American exhibition marks the launch of our arket awareness and sales activities for our newly cleared STERIZONE® VP4 Sterilizer,” stated R.M. (Ric) Rumble, President and CEO of TSO3. “We expect to meet with key decision-makers and influencers of the hospitals’ sterilization processes, and demonstrate the superior claims of our technology.”

TSO3 will be showcasing its STERIZONE® VP4 Technology at booth #536. Also, during the exhibit the Company has arranged a number of meetings with designers and manufacturers of medical equipment in order to demonstrate the strength of the technology compatibility and efficacy claims.

About the STERIZONE® VP4 low temperature Sterilizer

The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilization process. TSO3’s unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75-lbs load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014..

More information about the STERIZONE® VP4 Sterilizer is available through TSO3’s website, under the Products section:

About TSO3

TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company’s Web site at

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. 

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.


Back to Posts